|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: [email protected]. Type 508 Accommodation and the title of the report in the subject line of e-mail. Errata: Vol. 54, No. RR-16In the MMWR Recommendations and Reports, "A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) --- Part 1: Immunization of Infants, Children, and Adolescents," the following errors occurred: On page 8, in Table 2, in the first row, "Infants (<1 yr)," under the column heading "Combination vaccine, Pediarix, Dose (µg)," the text should read, "10." On page 9, in Table 4, under the column heading "Recommendation," the second bullet should read, "Administer 3 additional hepatitis B vaccine doses with single-antigen vaccine at ages 1, 2--3, and 6 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12--15 mos (Comvax)." The fourth bullet should read, "Test for HBsAg and antibody to HBsAg 1--2 mos after completion of >3 doses of a licensed hepatitis B vaccine series (i.e., at age 9--18 mos, generally at the next well-child visit). Testing should not be performed before age 9 mos nor within 4 wks of the most recent vaccine dose." The seventh bullet should read, "Administer 3 additional hepatitis B vaccine doses with single-antigen vaccine at ages 1, 2--3, and 6 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12--15 mos (Comvax)." The 10th bullet should read, "Complete the hepatitis B vaccine series with single-antigen vaccine at ages 2 mos and 6--18 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12--15 mos (Comvax)." The following footnote should be added to Table 4: "The final dose in the vaccine series should not be administered before age 24 weeks (164 days)." The corrected Table 4 is available in its entirety at http://www.cdc.gov/hepatitis/hbv/pdfs/correctedtable4.pdf.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to [email protected].Date last reviewed: 12/5/2007 |
|||||||||
|